Ataibeckley Inc

AtaiBeckley Shares Steady at $7.17 as CVR Valued at 42 Cents in Lilly Deal

AtaiBeckley shares remain flat at $7.17, 42 cents above Eli Lilly's cash offer, with the contingent value rights (CVR) implied at 16.8% of the $2.50 maximum payout.

Earnings Jul 28

AtaiBeckley Shares Trade Above Lilly Bid as Milestone Rights Valued at 18%

AtaiBeckley shares ended Monday at $7.19, above Eli Lilly's cash bid, as milestone rights are valued at $0.44, or 18% of the full $2.50 potential.

Markets Jul 20

AtaiBeckley Shares Reflect Merger CVR Valued at 19% of Par

AtaiBeckley shares surged 39.7% last week to $7.22, with the merger CVR valued at $0.47, representing 18.8% of its $2.50 maximum payout.

Markets Jul 19

AtaiBeckley Merger Value Reflects 14% of CVR Face Value

AtaiBeckley shares trade at $7.091, 34 cents above Eli Lilly's cash offer, implying a CVR value of 13.6% of its maximum $2.50 face value.

Markets Jul 17

Eli Lilly Shares Gain on Atai Deal with $1 Billion Milestone Potential

Eli Lilly shares edged up 1.08% on a $3.8B deal with Atai Life Sciences, which could unlock up to $1 billion in milestone payments for psychedelic depression drugs.

Markets Jul 16

AtaiBeckley Soars on Lilly Deal; Market Weighs Milestone Value

AtaiBeckley shares surged 31% to $7.04 after Eli Lilly agreed to acquire the company for up to $9.25 per share, including contingent payments. The stock sits just $0.29 above the cash offer, reflecting cautious market expectations for milestones.

Markets Jul 16

AtaiBeckley Surges on FDA Psychedelic Guidance, BPL-003 Duration Advantage

AtaiBeckley (ATAI) shares surged 15.6% as FDA staffing guidance for psychedelic trials boosted BPL-003's two-hour clinic model, potentially reducing monitoring costs vs. longer treatments.

Markets Jul 14

AtaiBeckley Surges as Phase 3 Trials for Depression Drug Begin

AtaiBeckley shares jumped 7.8% to $4.14 after announcing the start of Phase 3 trials for its lead depression drug BPL-003, with results expected in early 2029.

Technology Jun 16

Jupiter Neurosciences Shares Plunge on $100M MDMA Deal and Dilutive Offering

Jupiter Neurosciences shares fell 37% to $0.205 after announcing a $100M licensing deal for MDMA drug ALA-002 and a $2M stock offering, with trading volume exceeding 230 million shares.

Markets May 20